{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:51:12Z","timestamp":1761292272702},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,8,11]],"date-time":"2005-08-11T00:00:00Z","timestamp":1123718400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel\/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some patients do not respond to therapy. Our goals were to investigate whether <jats:italic>TUBB<\/jats:italic> mutations and mismatch repair defects underlie paclitaxel and cisplatin resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Thirty-four patients with primary ovarian carcinomas (26 serous and eight clear cell carcinomas) treated with paclitaxel\/cisplatin were analysed. <jats:italic>TUBB<\/jats:italic> exon 4 was analysed by nested PCR after a first round PCR using intronic primers. Microsatellite analysis was performed with the quasimonomorphic markers BAT 26 and BAT 34.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twenty-two of the 34 ovarian cancers (64.7%) presented residual tumour after surgery, seven of which (7\/22; 31.8%) were shown to be chemoresistant (five serous and two clear cell tumours). Sequence analysis did not find any mutation in <jats:italic>TUBB<\/jats:italic> exon 4. Microsatellite instability was not detected in any of the ovarian carcinomas.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We conclude that <jats:italic>TUBB<\/jats:italic> exon 4 mutations and mismatch repair defects do not play a significant role in paclitaxel\/cisplatin resistance.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-5-101","type":"journal-article","created":{"date-parts":[[2005,8,12]],"date-time":"2005-08-12T18:13:54Z","timestamp":1123870434000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel\/cisplatin"],"prefix":"10.1186","volume":"5","author":[{"given":"B\u00e1rbara","family":"Mesquita","sequence":"first","affiliation":[]},{"given":"Isabel","family":"Veiga","sequence":"additional","affiliation":[]},{"given":"Deolinda","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Isabel M","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Manuel R","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"S\u00e9rgio","family":"Castedo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2005,8,11]]},"reference":[{"key":"289_CR1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/S0959-8049(01)00267-2","volume":"37","author":"DM Parkin","year":"2001","unstructured":"Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: the global picture. Eur J Cancer. 2001, 37: S4-66. 10.1016\/S0959-8049(01)00267-2.","journal-title":"Eur J Cancer"},{"key":"289_CR2","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/S0140-6736(00)02074-2","volume":"355","author":"J Crown","year":"2000","unstructured":"Crown J, O'Leary M: The taxanes: an update. Lancet. 2000, 355: 1176-1178. 10.1016\/S0140-6736(00)02074-2.","journal-title":"Lancet"},{"key":"289_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuert G, Kaye S, Vargote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. J Natl Cancer Inst. 2000, 92: 699-708. 10.1093\/jnci\/92.9.699.","journal-title":"J Natl Cancer Inst"},{"key":"289_CR4","first-page":"340","volume":"25","author":"McGuire","year":"1998","unstructured":"McGuire , Ozols RF: Chemotherapy in advanced ovarian cancer. Semin Oncol. 1998, 25: 340-348.","journal-title":"Semin Oncol"},{"key":"289_CR5","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003, 3: 502-516. 10.1038\/nrc1123.","journal-title":"Nat Rev Cancer"},{"key":"289_CR6","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1002\/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J","volume":"88","author":"TH Wang","year":"2000","unstructured":"Wang TH, Wang HS, Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000, 88: 2619-2628. 10.1002\/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J.","journal-title":"Cancer"},{"key":"289_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/0014-4827(86)90084-4","volume":"163","author":"GA Floyd-Smith","year":"1986","unstructured":"Floyd-Smith GA, de Martinville B, Francke U: An expressed tubulin gene, TUBB, is located on the short arm of human chromosome 6 and two related sequences are dispersed on chromosome 8 and 13. Exp Cell Res. 1986, 163: 539-548. 10.1016\/0014-4827(86)90084-4.","journal-title":"Exp Cell Res"},{"key":"289_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0074-7696(08)62138-5","volume":"178","author":"RF Ludue\u00f1a","year":"1998","unstructured":"Ludue\u00f1a RF: Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol. 1998, 178: 207-275.","journal-title":"Int Rev Cytol"},{"key":"289_CR9","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0959-8049(98)00227-5","volume":"34","author":"RP Perez","year":"1998","unstructured":"Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 1998, 34: 1535-1542. 10.1016\/S0959-8049(98)00227-5.","journal-title":"Eur J Cancer"},{"key":"289_CR10","doi-asserted-by":"publisher","first-page":"17118","DOI":"10.1074\/jbc.272.27.17118","volume":"272","author":"P Giannakakou","year":"1997","unstructured":"Giannakakou P, Sackett DL, Kang YK, Zhan Z, Butters JT, Fojo T, Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant \u03b2-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997, 272: 17118-17125. 10.1074\/jbc.272.27.17118.","journal-title":"J Biol Chem"},{"key":"289_CR11","doi-asserted-by":"publisher","first-page":"23875","DOI":"10.1074\/jbc.274.34.23875","volume":"271","author":"ML Gonzalez-Garay","year":"1999","unstructured":"Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F: A \u03b2-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem. 1999, 271: 23875-23882. 10.1074\/jbc.274.34.23875.","journal-title":"J Biol Chem"},{"key":"289_CR12","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.1999.17.6.1786","volume":"17","author":"M Monz\u00f3","year":"1999","unstructured":"Monz\u00f3 M, Rosell R, Sanch\u00e9z JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY, Martin C: Paclitaxel resistance in non-small cell lung cancer associated with \u03b2-tubulin gene mutations. J Clin Oncol. 1999, 17: 1786-1793.","journal-title":"J Clin Oncol"},{"key":"289_CR13","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/jnci\/89.20.1537","volume":"89","author":"MM de las Alas","year":"1997","unstructured":"de las Alas MM, Aebi S, Fink D, Howell SB, Los G: Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst. 1997, 89: 1537-1541. 10.1093\/jnci\/89.20.1537.","journal-title":"J Natl Cancer Inst"},{"key":"289_CR14","first-page":"1061","volume":"84","author":"C Vaurs","year":"1997","unstructured":"Vaurs C, Bignon YJ: Quoi de neuf sur la signification des instabilit\u00e9s microssatellitaires dans les pathologies tumorales humaines?. Bull Cancer. 1997, 84: 1061-1071.","journal-title":"Bull Cancer"},{"key":"289_CR15","first-page":"1","volume":"4","author":"D Fink","year":"1998","unstructured":"Fink D, Aebi S, Howell SB: The role of DNA mismatch repair in drug resistance. Clin Cancer Res. 1998, 4: 1-6.","journal-title":"Clin Cancer Res"},{"key":"289_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s004320050258","volume":"125","author":"H Lage","year":"1999","unstructured":"Lage H, Dietel M: Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol. 1999, 125: 156-165. 10.1007\/s004320050258.","journal-title":"J Cancer Res Clin Oncol"},{"key":"289_CR17","first-page":"243","volume-title":"Handbook of Gynecologic Oncology","author":"SL Soignet","year":"2001","unstructured":"Soignet SL, Spriggs DR: General principles of chemotherapy. Handbook of Gynecologic Oncology. Edited by: Barakat RR, Bevers MW, Gershenson DM. 2001, London: Martin Dunitz, 243-263."},{"key":"289_CR18","first-page":"300","volume":"57","author":"JM Hoang","year":"1997","unstructured":"Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R: BAT \u2013 26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res. 1997, 57: 300-303.","journal-title":"Cancer Res"},{"key":"289_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4","volume":"21","author":"XP Zhou","year":"1998","unstructured":"Zhou XP, Hoang JM, Li YJ, Seruca R, Carneiro F, Sobrinho-Simoes M, Lothe RA, Gleeson CM, Russel SE, Muzeau F, Flejou JF, Hoang-Xuan L, Lidereau R, Thomas G, Hamelin R: Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer. 1998, 21: 101-107. 10.1002\/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4.","journal-title":"Genes Chromosomes Cancer"},{"key":"289_CR20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1128\/MCB.6.5.1379","volume":"6","author":"P Lamb","year":"1986","unstructured":"Lamb P, Crawford L: Characterization of the human P53 gene. Mol Cell Biol. 1986, 6: 1379-1385.","journal-title":"Mol Cell Biol"},{"key":"289_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","volume":"70","author":"JL Benedet","year":"2000","unstructured":"Benedet JL, Bender H, Jones H, Ngan HYS, Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000, 70: 209-262. 10.1016\/S0020-7292(00)90001-8.","journal-title":"Int J Gynaecol Obstet"},{"key":"289_CR22","first-page":"215","volume":"1","author":"S Sale","year":"2002","unstructured":"Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ, Sikic BI: Conservation of the class I \u03b2-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther. 2002, 1: 215-225.","journal-title":"Mol Cancer Ther"},{"key":"289_CR23","first-page":"681","volume":"23","author":"DE Lamendola","year":"2003","unstructured":"Lamendola DE, Duan Z, Penson RT, Oliva E, Seiden MV: Beta tubulin mutations are rare in ovarian carcinoma. Anticancer Res. 2003, 23: 681-686.","journal-title":"Anticancer Res"},{"key":"289_CR24","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/jnci\/93.24.1886","volume":"93","author":"MJ Kelley","year":"2001","unstructured":"Kelley MJ, Li S, Harpole DH: Genetic analysis of the \u03b2-tubulin gene, TUBB, in non-small-cell lung cancer. J Nat Cancer Inst. 2001, 93: 1886-1888. 10.1093\/jnci\/93.24.1886.","journal-title":"J Nat Cancer Inst"},{"key":"289_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ijc.10575","volume":"101","author":"S Hasegawa","year":"2002","unstructured":"Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Tamaki Y, Monden M, Nogushi S: Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer. 2002, 101: 46-51. 10.1002\/ijc.10575.","journal-title":"Int J Cancer"},{"key":"289_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0304-3835(03)00279-9","volume":"198","author":"K Maeno","year":"2003","unstructured":"Maeno K, Ito K, Hama Y, Shingu K, Kimura M, Sano M, Nakagomi H, Tsuchiaya S, Fujimori M: Mutation of the class I \u03b2-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett. 2003, 198: 89-97. 10.1016\/S0304-3835(03)00279-9.","journal-title":"Cancer Lett"},{"key":"289_CR27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10120-003-0235-6","volume":"6","author":"N Urano","year":"2003","unstructured":"Urano N, Fujiwara Y, Hasegawa S, Miyoshi Y, Nogushi S, Takiguchi S, Yasuda T, Yano M, Monden M: Absence of beta-tubulin gene mutation in gastric carcinoma. Gastric Cancer. 2003, 6: 108-112.","journal-title":"Gastric Cancer"},{"key":"289_CR28","doi-asserted-by":"publisher","first-page":"9495","DOI":"10.1073\/pnas.91.20.9495","volume":"91","author":"K Orth","year":"1994","unstructured":"Orth K, Hung J, Gazdar A, Bowcock A, Mathis JM, Sambrook J: Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci USA. 1994, 91: 9495-9499.","journal-title":"Proc Natl Acad Sci USA"},{"key":"289_CR29","first-page":"3087","volume":"56","author":"S Aebi","year":"1996","unstructured":"Aebi S, Haidar BK, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996, 56: 3087-3090.","journal-title":"Cancer Res"},{"key":"289_CR30","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/(SICI)1097-0215(19980831)77:5<741::AID-IJC13>3.0.CO;2-4","volume":"77","author":"D Fink","year":"1998","unstructured":"Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB: Enrichment for DNA mismatch repair deficient cells during treatment with cisplatin. Int J Cancer. 1998, 77: 741-746. 10.1002\/(SICI)1097-0215(19980831)77:5<741::AID-IJC13>3.0.CO;2-4.","journal-title":"Int J Cancer"},{"key":"289_CR31","first-page":"4881","volume":"56","author":"D Fink","year":"1996","unstructured":"Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nheme A, Christen RD, Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996, 56: 4881-4886.","journal-title":"Cancer Res"},{"key":"289_CR32","first-page":"1763","volume":"3","author":"S Aebi","year":"1997","unstructured":"Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Finj JL, Howell SB: Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res. 1997, 3: 1763-1767.","journal-title":"Clin Cancer Res"},{"key":"289_CR33","first-page":"1841","volume":"57","author":"D Fink","year":"1997","unstructured":"Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL, Howell SB: In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997, 57: 1841-1845.","journal-title":"Cancer Res"},{"key":"289_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/ijc.2910640602","volume":"64","author":"M Fujita","year":"1995","unstructured":"Fujita M, Enomoto T, Yoshino K, Nomura T, Buzard GS, Inoue M, Okudaira Y: Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer. 1995, 64: 361-366.","journal-title":"Int J Cancer"},{"key":"289_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/ijc.2910640614","volume":"64","author":"M Pieretti","year":"1995","unstructured":"Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE, Turker MS: Genetic alterations distinguish different types of ovarian tumors. Int J Cancer. 1995, 64: 434-440.","journal-title":"Int J Cancer"},{"key":"289_CR36","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/carcin\/17.9.1799","volume":"17","author":"II Arzimanoglou","year":"1996","unstructured":"Arzimanoglou II, Lallas T, Osborne M, Barber H, Gilbert F: Microsatellite instability differences between familial and sporadic ovarian cancers. Carcinogenesis. 1996, 17: 1799-1804.","journal-title":"Carcinogenesis"},{"key":"289_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/00004347-199904000-00010","volume":"18","author":"CJ Haas","year":"1999","unstructured":"Haas CJ, Diebold J, Hirschmann A, Rohrbach H, Schid S, Lohrs U: Microsatellite analysis in serous tumors of the ovary. Int J Gynecol Pathol. 1999, 18: 158-162.","journal-title":"Int J Gynecol Pathol"},{"key":"289_CR38","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/cncr.11770","volume":"98","author":"JP Geisler","year":"2003","unstructured":"Geisler JP, Goodheatr MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE: Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer. 2003, 98: 2199-2206. 10.1002\/cncr.11770.","journal-title":"Cancer"},{"key":"289_CR39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.humpath.2003.12.009","volume":"35","author":"KQ Cai","year":"2004","unstructured":"Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, Broaddus R, Liu J: Microsatellite instability and alteration of the expression of the hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004, 35: 552-559. 10.1016\/j.humpath.2003.12.009.","journal-title":"Hum Pathol"},{"key":"289_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ijc.20455","volume":"112","author":"G Singer","year":"2004","unstructured":"Singer G, Kallinowski T, Hartmann A, Dietmaier W, Wild PJ, Schraml P, Sauter G: Different types of microsatellite instability in ovarian carcinoma. Int J Cancer. 2004, 112: 643-646. 10.1002\/ijc.20455.","journal-title":"Int J Cancer"},{"key":"289_CR41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0006-2952(97)83383-7","volume":"53","author":"H Parekh","year":"1997","unstructured":"Parekh H, Wiesen K, Simpkins H: Acquisition of taxol resistance via P-glycoprotein and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol. 1997, 53: 461-470. 10.1016\/S0006-2952(97)83383-7.","journal-title":"Biochem Pharmacol"},{"key":"289_CR42","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/bjc.1998.91","volume":"77","author":"S Ranganathan","year":"1998","unstructured":"Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR: Altered \u03b2-tubulin isotype expression in paclitaxel resistant human prostate carcinoma cells. Brit J Cancer. 1998, 77: 562-566.","journal-title":"Brit J Cancer"},{"key":"289_CR43","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/sj.bjc.6690507","volume":"80","author":"M Kavallaris","year":"1999","unstructured":"Kavallaris M, Burkhart CA, Horowitz SB: Antisense oligonucleotides to class III \u03b2-tubulin sensitize drug-resistant cells to Taxol. Brit J Cancer. 1999, 80: 1020-1025. 10.1038\/sj.bjc.6690507.","journal-title":"Brit J Cancer"},{"key":"289_CR44","first-page":"229","volume":"57","author":"S Haldar","year":"1997","unstructured":"Haldar S, Basu A, Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997, 57: 229-233.","journal-title":"Cancer Res"},{"key":"289_CR45","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1006\/gyno.1998.5125","volume":"70","author":"JR Liu","year":"1998","unstructured":"Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V: Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol. 1998, 70: 398-403. 10.1006\/gyno.1998.5125.","journal-title":"Gynecol Oncol"},{"key":"289_CR46","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.1998.16.8.2583","volume":"16","author":"YT Tai","year":"1998","unstructured":"Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SH: BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol. 1998, 16: 2583-2590.","journal-title":"J Clin Oncol"},{"key":"289_CR47","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1023\/A:1008265012435","volume":"9","author":"P Perego","year":"1998","unstructured":"Perego P, Romanelli S, Carenini N, Magnani I, Leone R, Bonetti A, Paolicchi A, Zunino F: Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to taxol. Ann Oncol. 1998, 9: 423-430. 10.1023\/A:1008265012435.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-5-101\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:45:24Z","timestamp":1630449924000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-5-101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,11]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["289"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-5-101","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,11]]},"assertion":[{"value":"26 April 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"101"}}